T1	Condition 18 33	prostate cancer
T2	Drug 67 79	GnRH agonist
T3	Drug 67 71;83 93	GnRH antagonist
*	OR T2 T3
T4	Multiplier 102 122	for at least 1 month
T5	Temporal 123 142	prior to enrollment
T6	Procedure 52 61	treatment
T7	Scope 67 93	GnRH agonist or antagonist
R1	Has_scope Arg1:T6 Arg2:T7	
R2	Has_multiplier Arg1:T6 Arg2:T4	
R3	Has_temporal Arg1:T6 Arg2:T5	
T8	Non-query-able 145 403	Willing and able to complete survey questionnaires in English without assistance through the duration of the study. This stipulation is in place because not all of the proposed quality of life or cognitive tests are available or validated in other languages.
T9	Person 405 408	Age
T10	Value 409 419	= 18 years
R4	Has_value Arg1:T9 Arg2:T10	
T11	Non-query-able 422 577	Ability to understand and the willingness to sign a written informed consent document written in English that is approved by an institutional review board.
T12	Qualifier 607 617	metastatic
T13	Qualifier 618 635	hormone sensitive
T14	Condition 636 651	prostate cancer
T15	Condition 653 658	mHSPC
R5	Has_qualifier Arg1:T14 Arg2:T13	
R6	Has_qualifier Arg1:T14 Arg2:T12	
T16	Scope 607 651	metastatic hormone sensitive prostate cancer
R7	Subsumes Arg1:T15 Arg2:T16	
T17	Qualifier 663 683	castration-resistant
T18	Qualifier 684 694	metastatic
T19	Condition 695 710	prostate cancer
T20	Condition 712 717	mCRPC
R8	Has_qualifier Arg1:T19 Arg2:T18	
R9	Has_qualifier Arg1:T19 Arg2:T17	
T21	Scope 663 710	castration-resistant metastatic prostate cancer
R10	Subsumes Arg1:T20 Arg2:T21	
T22	Drug 758 777	abiraterone acetate
T23	Procedure 743 752	treatment
T24	Condition 779 784	mHSPC
T25	Condition 788 793	mCRPC
*	OR T24 T25
T26	Drug 798 810	enzalutamide
T27	Condition 812 817	mCRPC
T28	Scope 758 817	abiraterone acetate (mHSPC or mCRPC) or enzalutamide (mCRPC
T29	Scope 798 818	enzalutamide (mCRPC)
T30	Scope 758 794	abiraterone acetate (mHSPC or mCRPC)
*	OR T30 T29
R11	Has_scope Arg1:T23 Arg2:T28	
T31	Scope 663 818	castration-resistant metastatic prostate cancer (mCRPC) and eligible to undergo treatment with abiraterone acetate (mHSPC or mCRPC) or enzalutamide (mCRPC)
*	OR T16 T31
T32	Procedure 1124 1136	chemotherapy
T33	Qualifier 1141 1158	hormone-sensitive
T34	Qualifier 1159 1169	metastatic
T35	Condition 1170 1185	prostate cancer
R12	Has_qualifier Arg1:T35 Arg2:T34	
R13	Has_qualifier Arg1:T35 Arg2:T33	
R14	AND Arg1:T32 Arg2:T35	
T36	Multiplier 1213 1242	lasted for more than 6 months
T37	Negation 1204 1207	not
R15	Has_negation Arg1:T36 Arg2:T37	
R16	Has_multiplier Arg1:T32 Arg2:T36	
T38	Temporal 1244 1313	At least 12 months must have elapsed since completion of chemotherapy
T39	Reference_point 1287 1313	completion of chemotherapy
T40	Procedure 1301 1313	chemotherapy
R17	multi Arg1:T39 Arg2:T40	
R18	Has_index Arg1:T38 Arg2:T39	
R19	Has_temporal Arg1:T32 Arg2:T38	
T41	Temporal 1343 1348	prior
T42	Qualifier 1349 1359	definitive
T43	Procedure 1360 1377	radiation therapy
T44	Procedure 1381 1388	surgery
*	OR T43 T44
T45	Scope 1360 1388	radiation therapy or surgery
R20	Has_qualifier Arg1:T45 Arg2:T42	
R21	Has_temporal Arg1:T45 Arg2:T41	
T46	Temporal 1390 1484	At least 60 days must have elapsed since completion of definitive radiation therapy or surgery
T47	Procedure 1456 1473	radiation therapy
T48	Procedure 1477 1484	surgery
*	OR T47 T48
T49	Qualifier 1445 1455	definitive
T50	Reference_point 1431 1484	completion of definitive radiation therapy or surgery
R22	Has_index Arg1:T46 Arg2:T50	
T51	Qualifier 1512 1527	grade 2 or less
T52	Condition 1528 1543	adverse effects
R23	Has_qualifier Arg1:T52 Arg2:T51	
T53	Temporal 1544 1571	at the time of registration
T54	Non-representable 1573 1696	Enrollment during palliative radiation of = 10 days, or radiation of = 10 days during the duration of the study is allowed.
R24	Has_temporal Arg1:T52 Arg2:T53	
R25	Has_temporal Arg1:T45 Arg2:T46	
T55	Non-query-able 1698 1743	Patients must be able to take oral medication
